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MaBACKGROUND Non–vitamin K oral anticoagulants (NOACs) do not require routine laboratory monitoring. However,
laboratory measurement may be desirable in special situations and populations.
OBJECTIVES This study’s objective was to systematically review and summarize current evidence regarding laboratory
measurement of the anticoagulant activity of dabigatran, rivaroxaban, and apixaban.
METHODS We searched PubMed and Web of Science for studies that reported a relationship between drug levels of
dabigatran, rivaroxaban, and apixaban and coagulation assay results. Study quality was evaluated using QUADAS-2
(Quality Assessment of Diagnostic Accuracy Studies 2).
RESULTS We identiﬁed 17 eligible studies for dabigatran, 15 for rivaroxaban, and 4 for apixaban. For dabigatran,
a normal thrombin time excludes clinically relevant drug concentrations. The activated partial thromboplastin time
(APTT) and prothrombin time (PT) are less sensitive and may be normal at trough drug levels. The dilute thrombin time
(R2 ¼ 0.92 to 0.99) and ecarin-based assays (R2 ¼ 0.92 to 1.00) show excellent linearity across on-therapy drug con-
centrations and may be used for drug quantiﬁcation. For rivaroxaban and apixaban, anti-Xa activity is linear (R2 ¼ 0.89
to 1.00) over a wide range of drug levels and may be used for drug quantiﬁcation. Undetectable anti-Xa activity likely
excludes clinically relevant drug concentrations. The PT is less sensitive (especially for apixaban); a normal PT may not
exclude clinically relevant levels. The APTT demonstrates insufﬁcient sensitivity and linearity for quantiﬁcation.
CONCLUSIONS Dabigatran, rivaroxaban, and apixaban exhibit variable effects on coagulation assays. Understanding
these effects facilitates interpretation of test results in NOAC-treated patients. More information on the relationship
between drug levels and clinical outcomes is needed. (J Am Coll Cardiol 2014;64:1128–39) © 2014 by the American
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AB BR E V I A T I O N S
AND ACRONYM S
ACT = activated clotting time
AF = atrial ﬁbrillation
APTT = activated partial
thromboplastin time
ECA = ecarin chromogenic
assay
ECT = ecarin clotting time
NOAC = non–vitamin K oral
anticoagulant
PiCT = prothrombinase-
induced clotting time
POC = point of care
PT/INR = prothrombin time/
international normalized ratio
TT = thrombin time
VKA = vitamin K antagonist
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1129agents collectively as non–vitamin K oral anticoagu-
lants (NOACs) in this paper. Synonymous terms
preferred by other researchers include direct-acting
oral anticoagulant agents and new, novel, or target-
speciﬁc oral anticoagulant agents (1).
Unlike warfarin and other vitamin K antagonists
(VKAs), the NOACs are administered in ﬁxed doses and
do not require routine laboratory monitoring (2–4).
However, measurement of their anticoagulant activ-
ity may be desirable in special clinical settings such
as bleeding; the pre-operative state; breakthrough
thrombosis; and suspected overdose, noncompli-
ance, or drug interactions and in certain populations,
including those with extremes in body weight and
in the elderly and patients with renal insufﬁciency
in whom there is a risk of drug accumulation.
Assessment of anticoagulant effect may also be
important in patients with AF presenting with acute
ischemic stroke before administration of thrombo-
lytic therapy (5).SEE PAGE 1140Numerous studies on use of coagulation assays for
measurement of NOAC activity have been published
recently, although a systematic review has not been
undertaken. The objective of our analysis was to
summarize current evidence regarding laboratory
measurement of NOAC anticoagulant activity and to
provide evidence-based guidance to practicing car-
diologists on the interpretation of coagulation tests in
NOAC-treated patients.
METHODS
LITERATURE SEARCH. We performed a systematic
review of the literature to examine current evi-
dence for laboratory measurement of the NOACs.
A search of PubMed and Web of Science from incep-
tion through December 1, 2013, was undertaken
separately for dabigatran, rivaroxaban, and
apixaban using the following key words: “name of
drug” AND ((laboratory measurement) OR (laboratory
monitoring)).
STUDY SELECTION. Articles were examined, ﬁrst by
title and abstract and then by review of the complete
paper as indicated. Additional articles were sought by
reviewing bibliographies. Liquid chromatography/
tandem mass spectrometry (LC-MS/MS) is the refer-
ence method for measurement of the plasma con-
centration of NOACs (6). Studies that reported the
relationship between drug (or active metabolite)
levels in human plasma, as measured directly using
LC-MS/MS or indirectly using LC-MS/MS–validatedcalibration standards and 1 or more clinical
coagulation assays, were eligible for inclu-
sion. We excluded animal studies, abstracts
only, and non–English language publications.
DATA EXTRACTION. We extracted key char-
acteristics from eligible studies and recorded
them in an evidence table. These included
author, year of publication, setting, NOAC
(i.e., dabigatran, rivaroxaban, or apixaban),
reference method for measurement of drug
levels, range of drug concentrations studied,
test material (i.e., ex vivo patient plasma,
ex vivo healthy control plasma, or spiked
normal plasma), dose (for studies using
ex vivo plasma only), indication (for studies
using ex vivo patient plasma only), number
of samples (for studies using individual
[i.e., unpooled] plasma only), coagulation
assays and reagents, and descriptors of the relation-
ship between drug level and coagulation assay (e.g.,
R2 values, range of linearity).
QUALITY ASSESSMENT. Study quality was evaluated
using QUADAS-2 (Quality Assessment of Diagnostic
Accuracy Studies 2), a standardized tool for quality
assessment of studies of diagnostic accuracy. The tool
comprises 4 domains: patient selection, index test,
reference standard, and ﬂow and timing. Risk of bias
is assessed across all domains; the ﬁrst 3 domains are
also assessed with respect to applicability to clinical
practice (7).
RESULTS
DABIGATRAN. Dabigatran etexilate, an oral non-
peptide prodrug, is rapidly converted to the active
drug dabigatran by ubiquitous esterases. Dabigatran
directly inhibits both free and clot-bound thrombin.
It has relatively poor bioavailability (approximately
6.5%) and is eliminated predominantly by the kidneys
(80%). In individuals with normal renal function, the
half-life of dabigatran is 12 to 14 h. Prolonged clear-
ance and bioaccumulation are observed in patients
with renal insufﬁciency (8). In patients with non-
valvular AF and normal kidney function, the dose is
150 mg twice daily, which is reduced in patients with
renal insufﬁciency.
Peak levels of dabigatran occur 2 to 3 h after
ingestion. Steady-state peak and trough concentra-
tions in patients with AF and normal renal function
taking dabigatran 150 mg twice daily are shown in
Table 1 (8). Substantial interindividual variability in
drug exposure is observed. In the PETRO (Preven-
tion of Embolic and Thrombotic Events in Patients
TABLE 1 Expected Steady-State Peak and Trough Concentrations
of Dabigatran, Rivaroxaban, and Apixaban Derived From
Pharmacokinetic Studies
Drug Dose
Study
Population
Peak,
ng/ml
Trough,
ng/ml Ref. #
Dabigatran 150 mg bid Patients with AF 184* 90* (9,10)
Rivaroxaban 20 mg qd Patients with AF 274† 30† (33)
Apixaban 5 mg bid Healthy male
volunteers
129‡ 50‡ (52)
Only standard doses approved for AF are shown. *Median. †Median estimated by
mathematical modeling. ‡Mean.
AF ¼ atrial ﬁbrillation; bid ¼ twice daily; qd ¼ once daily.
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1130With Persistent Atrial Fibrillation) study, the range
(5th to 95th percentile) in peak and trough con-
centrations in patients taking 150 mg twice daily
was 64 to 443 ng/ml and 31 to 225 ng/ml, respec-
tively (9,10).160 articles
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apixaban literature searches.Study se lect ion . Our literature search yielded 160
articles. Nine additional references were identiﬁed
from bibliographies. A total of 152 articles were
excluded: 135 did not report an original research
study, 14 did not report drug levels measured by
LC-MS/MS, and 3 were published as abstracts only.
The remaining 17 articles (11–27) met eligibility
criteria (Figure 1). Eligible studies were collectively
conducted in 9 different countries across a range of
dabigatran concentrations from 0 to 1,886 ng/ml.
Only 4 studies used ex vivo plasma from dabigatran-
treated patients; the remainder involved ex vivo
healthy volunteer plasma or normal plasma spiked
in vitro with dabigatran as the test material
(Table 2).
Act ivated part ia l thromboplast in t ime. Twelve
eligible studies reported a relationship between
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TABLE 2 Characteristics of Eligible Dabigatran Studies
Ref. # Setting
Range of Drug
Concentrations,
ng/ml Test Material Indication (n) Dose, mg
Coagulation
Test R2
(10) Germany NR Ex vivo patient plasma MOS (287) 12.5–300 bid;
150–300 qd
APTT
ECT
NR
NR
(11) Germany NR Ex vivo healthy volunteer plasma NA (80) 10–400 SD;
50–400 tid
APTT
ECT
PT/INR
TT
0.85
0.92–0.96
0.83–0.85
0.60–0.86
(12) Germany NR Ex vivo healthy volunteer plasma NA (35) 150 bid APTT
ECT
NR
NR
(13) Sweden 0–1,000 Spiked normal pooled plasma NA (NA) NA APTT
PT/INR
NR
NR
(14) United States 0–500 Spiked normal pooled plasma NA (NA) NA APTT
Dilute TT
TT
0.95*
0.98
NR
(15) United States,
United Kingdom,
Canada
25–500 Spiked normal pooled plasma NA (NA) NA APTT
PT/INR
TT
0.96
0.99
NR
(16) Belgium 4.7–943 Spiked normal pooled plasma NA (NA) NA APTT
Dilute PT
Dilute TT
ECA
ECT
PiCT
PT/INR
TT
0.96–0.99
NR
0.99
0.99
1.00
NR
NR
NR
(17) Austria 0–480 Spiked normal pooled plasma NA (NA) NA APTT
PT/INR
NR
NR
(18) Germany 0–1,000 Spiked normal pooled plasma NA (NA) NA APTT
ECT
PT/INR
NR
NR
NR
(19) New Zealand 30–960 Spiked normal pooled plasma NA (NA) NA Dilute TT NR
(20) Germany 0–1,886 Spiked normal pooled plasma NA (NA) NA Dilute TT 0.99
(21) Germany 50–1,400 Spiked healthy volunteer plasma NA (4) NA POC-INR
PT/INR
NR
NR
(22) Sweden <0.5–586 Ex vivo patient plasma AF (70) NR APTT
Dilute TT
ECA
PT/INR
0.58
0.97
0.96
0.48
(23) United States 0–500 Ex vivo patient plasma
Spiked normal pooled plasma
AF (NR)
VTE (NR)
NA (NA)
150 bid
NA
Dilute TT
ECA
0.96–0.97
0.99
(24) United States 18–487 Ex vivo patient plasma AF (29)
VTE (6)
NR ACT
APTT
Dilute TT
ECA
ECT
PT/INR
TT
0.71
0.74–0.82
0.92
0.94–0.99
0.98
0.60–0.86
0.75–0.97
(25) Sweden 0–985.5 Spiked normal pooled plasma NA (NA) NA PT/INR NR
(26) Finland 120–300 Spiked normal pooled plasma NA (NA) NA APTT
PT/INR
TT
NR
NR
NR
*Relationship described by second-order polynomial regression.
ACT¼ activated clotting time; APTT ¼ activated partial thromboplastin time; ECA ¼ ecarin chromogenic assay; ECT¼ ecarin clotting time; INR ¼ international normalized ratio; MOS¼major
orthopedic surgery; NA ¼ not applicable; NR ¼ not reported; PiCT ¼ prothrombinase-induced clotting time; POC ¼ point of care; PT ¼ prothrombin time; SD ¼ single dose; tid ¼ 3 times daily;
TT ¼ thrombin time; VTE ¼ venous thromboembolism; other abbreviations as in Table 1.
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normal plasma spiked with dabigatran in vitro
(Table 2). Dabigatran prolonged the APTT in a
concentration-dependent manner in both ex vivo
and in vitro studies. The dose response was linearup to a concentration of 200 to 300 ng/ml and then
ﬂattened out at higher drug levels (17,28). This
curvilinear relationship did not permit quantitative
assessment of dabigatran levels, particularly at
higher concentrations.
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sensitivity to dabigatran. The APTT of plasma spiked
with dabigatran 120 ng/ml ranged from 26.0 to
91.9 s in a cross-validation study of 9 different APTT
methods (27). These ﬁndings suggest that coagulation
laboratories should perform dose-response studies
using calibration standards to determine the sensi-
tivity of their particular APTT method to dabigatran
and communicate the results to clinicians. The least
sensitive reagents required a dabigatran concentra-
tion of approximately 400 ng/ml to produce a 2-fold
prolongation in the APTT over control (19). The
APTT may not be prolonged in the presence of
typical on-therapy trough levels (Table 1), particularly
if a relatively insensitive reagent is used. In a study
of ex vivo plasma from patients taking dabigatran
150 mg twice daily, 18% of participants had a normal
APTT at trough (25). In another study of patients with
AF, some samples had an APTT within the normal
range despite dabigatran concentrations as high as
60 ng/ml (23).
Prothrombin t ime/ internat iona l normal i zed
rat io . Eleven studies reported a relationship be-
tween dabigatran levels and the prothrombin time/
international normalized ratio (PT/INR). Eight used
spiked plasma, 2 ex vivo patient plasma, and 1 ex vivo
plasma from healthy volunteers (Table 2). Dabigatran
prolonged the PT in a concentration-dependent
manner, as deﬁned by an exponential (i.e., non-
linear) relationship (17). The PT/INR was less sensi-
tive to dabigatran than the APTT. In an ex vivo
study of patients with AF, an INR of 1.2 or greater
was only observed with dabigatran concentrations
in excess of 400 ng/ml (23).
As with APTT, commercial PT reagents differ in
their sensitivity to dabigatran. In a survey of 71
coagulation laboratories, the PT of plasma spiked to a
concentration of 300 ng/ml ranged from 15.7 to 50.2 s,
depending on the reagent (27). PT may be measured
using 2 assay types. The Quick method is inﬂuenced
by the entire extrinsic and common pathways of
coagulation, whereas the Owren method is affected
only by factors II, VII, and X. In studies of spiked
plasma, Quick PT reagents were more sensitive to
dabigatran than Owren reagents (14,27).
Point-of-care devices are available for measuring
the INR (POC-INR) in whole blood in VKA-treated
patients. In one study assessing the relationship
between dabigatran levels and a single POC-INR
system, the POC system yielded INR values 2- to
4-fold higher than those obtained using a laboratory
PT/INR method. Dabigatran concentrations >500
ng/ml were beyond the POC system’s limit of
detection (22).Thrombin t ime. Six studies reported a relationship
between thrombin time (TT) and dabigatran levels
(Table 2). The TT (in unmodiﬁed form) was inordi-
nately sensitive in both ex vivo and in vitro studies.
Depending on the reagent, dabigatran concentrations
of as little as 25 and up to 150 ng/ml exceeded the
limits of detection (15–17,28).
Di lute TT . In the dilute TT assay, the excessive
sensitivity of the TT is overcome by diluting the
plasma sample (21). Seven studies reported a rela-
tionship between the dilute TT and dabigatran con-
centration (Table 2). Two studies used an in-house
modiﬁcation of the TT (15,20); 5 used the HEMO-
CLOT thrombin inhibitor assay (HYPHEN BioMed,
Neuvillesur-Oise, France), a commercially available
dilute TT test (17,21,23–25). Dabigatran prolonged the
assay in a concentration-dependent manner. The
relationship showed a high degree of linearity, with
R2 values ranging between 0.92 and 0.99 in both
in vitro and ex vivo studies. The lower limit of
detection according to the manufacturer is 50 ng/ml
(21). Two studies determined the assay to be less
accurate and more variable at concentrations below
50 to 100 ng/ml (15,21). The dilute TT is currently not
widely available; in a recent survey in Australia and
New Zealand, only 9 of 592 laboratories reported
using it (29).
Ecar in-based assays . Ecarin is a snake venom that
cleaves prothrombin to form meizothrombin, an un-
stable intermediate of thrombin. Dabigatran inhibits
the thrombin-like activity of meizothrombin (24).
Two assays use ecarin as an activator: the ecarin
clotting time (ECT) and ecarin chromogenic assay
(ECA).
Six studies reported a relationship between ECT
and dabigatran levels (Table 2). Both in vitro and
ex vivo studies demonstrated a high degree of line-
arity, with R2 values ranging between 0.92 and 1.00.
Loss of linearity was observed in 2 studies at dabiga-
tran levels in excess of 470 to 500 ng/ml (17,19). A
relationship between ECA and drug levels was re-
ported in 4 studies (Table 2). The relationship was
linear, with R2 values of 0.94 to 0.99 in in vitro and
ex vivo samples. One study identiﬁed greater vari-
ability at dabigatran concentrations <50 ng/ml (23).
The ECT and ECA are hampered by lack of standardi-
zation, variability in sensitivity to dabigatran among
different lots of ecarin, and limited availability (17,20).
Other assays . Relationships between dabigatran
level and the dilute PT, prothrombinase-induced
clotting time (PiCT), and activated clotting time
(ACT) were each reported in a single study. Both the
dilute PT and PiCT evinced a complex nonlinear
dose-response curve (17). As with heparin, the ACT
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1133proved insensitive to lower concentrations of dabi-
gatran. In an ex vivo study, the ACT was normal in
40% of trough samples despite on-therapy dabigatran
levels (25).
RIVAROXABAN. Rivaroxaban is an oral inhibitor of
free and clot-associated factor Xa through reversible,
competitive interactions with its active site (30).
Bioavailability following oral administration is dose
dependent (80% to 100% following a 10-mg dose;
66% following a 20-mg dose). It is highly bound to
plasma proteins (>90%) (31); plasma levels peak 2 to
4 h following oral administration (32,33). Partially
excreted by the kidneys (36%), rivaroxaban has a
half-life of 6 to 13 h depending on dose and age
(31–35). Table 1 shows expected peak and trough
plasma concentrations in patients with AF treated
with 20 mg daily (36).
Study se lect ion . Our literature search yielded
134 unique rivaroxaban articles. Two additionalTABLE 3 Characteristics of Eligible Rivaroxaban Studies
Ref. # Setting
Range of Drug
Concentration,
ng/ml Test M
(26) Europe 60–305 Spiked normal p
(36) United States, Canada <10–>1,000 Spiked normal p
(37) France 0–1,000 Spiked normal p
(38) France NR Ex vivo patient
(39) Germany 25–900 Spiked normal p
(40) Sweden 0–1,000 Spiked normal p
(41) Italy 100–700 Spiked normal p
(42) Switzerland 40–150 Ex vivo healthy
Spiked normal p
(43) Germany 1.9–283.0 Ex vivo patient
(44) the Netherlands 0–1,000 Spiked normal p
(45) Europe, North America 20–662 Spiked normal p
(46) Europe, North America 19–643 Spiked normal p
(47) the Netherlands 0–800 Spiked normal p
(48) Belgium NR Ex vivo patient
(49) France NR Ex vivo patient
*Relationship described by second-order polynomial regression.
RVVT ¼ Russell viper venom time; other abbreviations as in Tables 1 and 2.references were identiﬁed from bibliographies. We
excluded 121 articles: 108 did not report an original
research study, 12 did not report a relationship be-
tween a coagulation assay and drug levels measured
by LC-MS/MS, and 1 was published as an abstract
only. The remaining 15 articles (27,37–50) met eligi-
bility criteria (Figure 1). Rivaroxaban concentrations
in eligible studies ranged from 0 to >1,000 ng/ml.
Four studies used ex vivo plasma from rivaroxaban-
treated patients, 1 incorporated ex vivo plasma from
healthy controls, and the remainder used normal
plasma spiked in vitro with rivaroxaban (Table 3).
Prothrombin t ime . We found 11 studies evaluating
the effect of rivaroxaban on PT (Table 3). In general,
rivaroxaban prolonged the PT in a concentration-
dependent, linear fashion in plasma spiked with
rivaroxaban and in plasma from patients receiving
rivaroxaban for approved indications. On-therapy
rivaroxaban concentrations showed a modest effectaterial Indication (n) Dose, mg
Coagulation
Test R2
ooled plasma NA (NA) NA Anti-Xa
APTT
PT/INR
NR
NR
NR
ooled plasma NA (NA) NA PT/INR NR
ooled plasma NA (NA) NA Anti-Xa
APTT
Dilute PT
Dilute RVVT
PiCT
POC-INR
PT/INR
NR
0.90–0.98
0.97–0.99
0.99
NR
1.00
0.99–1.00
plasma MOS (166) 10 qd Anti-Xa
APTT
PT/INR
0.97–1.00
0.75
0.47
ooled plasma NA (NA) NA Anti-Xa NR
ooled plasma NA (NA) NA Anti-Xa
APTT
PT/INR
NR
NR
NR
ooled plasma NA (NA) NA PT/INR NR
volunteer plasma
ooled plasma
NA (20)
NA (NA)
10 qd
NA
Anti-Xa 0.98–0.99
plasma MOS (80) 10 qd Anti-Xa 1.00
ooled plasma NA (NA) NA Anti-Xa
APTT
PT/INR
NR
1.00
1.00*
ooled plasma NA (NA) NA Anti-Xa NR
ooled plasma NA (NA) NA PT/INR NR
ooled plasma NA (NA) NA PT/INR 1.00
plasma AF, VTE (52) NR Anti-Xa
PT/INR
0.95
0.58–0.66
plasma MOS (41) 10 qd Anti-Xa
PT/INR
0.99
NR
TABLE 4 Characteristics of Eligible Apixaban Studies
Ref. # Setting
Range of Drug
Concentration, ng/ml Test Material Indication (n) Dose, mg
Coagulation
Test R2
(36) United States, Canada <10–>1,000 Ex vivo patient plasma
Spiked normal pooled plasma
VTE (348)
NA (NA)
5–10 bid, 20 qd
NA
Anti-Xa
PT/INR
0.88–0.89
0.36
(53) Global 1–933 Ex vivo patient plasma ACS (1,691) 5–20 qd Anti-Xa 0.97
(54) United States 0–2,500 Ex vivo healthy volunteer plasma
Spiked healthy volunteer plasma
NA (39)
NA (21)
20 SD
NA
PT/INR 0.41
(55) France 0–1,000 Spiked normal pooled plasma NA (NA) NA Anti-Xa
APTT
PT/INR
NR
NR
NR
ACS ¼ acute coronary syndrome; other abbreviations as in Tables 1 and 2.
Cuker et al. J A C C V O L . 6 4 , N O . 1 1 , 2 0 1 4
Laboratory Testing of Anticoagulants S E P T E M B E R 1 6 , 2 0 1 4 : 1 1 2 8 – 3 9
1134on PT. Typical trough (41 to 60 ng/ml) and peak
(219 to 305 ng/ml) concentrations increased PT by 6%
to 19% and 50% to 135%, respectively (27,38,42,47).
Assay sensitivity varied signiﬁcantly among throm-
boplastin reagents. Interassay variability was reduced
by use of an international sensitivity index speciﬁc
for rivaroxaban but not by conversion to an INR
used for monitoring VKA therapy (38,42). These
observations suggest that coagulation laboratories
should perform dose-response studies using calibra-
tion standards to determine the sensitivity of their
particular PT method for rivaroxaban and communi-
cate the results to clinicians.
Act ivated part ia l thromboplast in t ime. Five
studies evaluated the effect of rivaroxaban on APTT
(Table 3). Whereas rivaroxaban prolonged APTT in a
dose-dependent manner, the overall relationship
between rivaroxaban concentration and APTT pro-
longation was nonlinear, with studies reporting
conﬂicting data regarding the concentration ranges
over which nonlinearity was most pronounced
(27,41,45). Similar to PT results, there was signiﬁcant
variability among reagents and among individual
laboratories in a multicenter study (27,45). Hillarp
et al. (41) reported that the APTT assay was insensi-
tive at the lowest drug level studied (25 ng/ml).
Ant i -Xa act iv i ty . Ten studies assessed the effect
of rivaroxaban on anti-Xa activity (Table 3). In
general, the studies showed a linear, concentration-
dependent relationship between rivaroxaban con-
centration and anti-Xa activity over a wide range of
concentrations (e.g., 20 to 660 ng/ml) when they were
measured using a standard curve generated with
rivaroxaban calibrators and controls with R2 values
ranging from 0.95 to 1.00 (39,43,44,49,50). The cor-
relation was less robust at concentrations <100 ng/ml
(49). However, Samama et al. (46) demonstrated that
low rivaroxaban concentrations could be measured
with a modiﬁed anti-Xa test using less dilutedsamples. Investigators found a greater degree of
assay imprecision at higher rivaroxaban concentra-
tions (800 ng/ml) in one study (45). In a multicenter
study, both intralaboratory and interlaboratory pre-
cision were satisfactory except at the lower limit of
detection (20 ng/ml); use of a centrally distributed
reagent reduced interlaboratory variability (46).
Mathematical modeling also decreased interassay
variability resulting from different sensitivities of
individual reagents to rivaroxaban (40). When com-
mercial anti-Xa assays were used with unfractionated
or low-molecular-weight heparin (LMWH) calibrators
(rather than rivaroxaban calibrators), the relationship
remained linear up to a rivaroxaban concentration of
500 ng/ml (38,41).
Other assays . The relationship between rivaroxaban
concentration and the dilute PT, dilute Russell viper
venom time (dRVVT), and PiCT was evaluated in
a single study (38). Researchers uncovered a linear,
dose-dependent relationship between rivaroxaban
and the dilute PT. Rivaroxaban increased the
dRVVT ratio (expressed as ratio vs. baseline) in a
concentration-dependent but nonlinear manner. At
low concentrations of rivaroxaban (<200 ng/ml),
there was a paradoxical shortening of PiCT, whereas
PiCT was prolonged in a concentration-dependent
fashion at higher concentrations.
APIXABAN. Like rivaroxaban, apixaban is a small,
orally available, direct inhibitor of coagulation factor
Xa (51). It has 50% bioavailability and, in healthy
volunteers, reaches its maximum plasma concentra-
tion approximately 3 h after ingestion. Apixaban is
highly protein bound in plasma, and concomitant
food intake has little impact on its pharmacokinetics
(52). Metabolized through multiple routes, apixaban
is less dependent on renal clearance than dabigatran
and rivaroxaban. In persons with normal renal
function, apixaban has a half-life of approximately
12 h (53). As measured by LC-MS/MS, the expected
TABLE 5 Study Quality Assessment Using QUADAS-2 Criteria
Ref. #
Risk of Bias Applicability Concerns
Patient
Selection
Index
Test
Reference
Standard
Flow and
Timing
Patient
Selection
Index
Test
Reference
Standard
Dabigatran studies
(10) L U U L L H H
(11) NA U U L H H H
(12) NA U U L H H H
(13) NA U L L H L H
(14) NA U L L H H H
(15) NA L L L H L H
(16) NA U L L H H H
(17) NA U L L H L H
(18) NA U L L H H H
(19) NA U L L H H H
(20) NA U L L H H H
(21) NA U L L H L H
(22) U U U L L H H
(23) U U U L L H H
(24) U U U L L H H
(25) NA U L L H L H
(26) NA U L L H L H
Rivaroxaban studies
(26) NA U U L H L H
(36) NA U U L L L H
(37) NA U L L H H H
(38) U U U L L L H
(39) NA U L L H L H
(40) NA U L L H L H
(41) NA U L L H L H
(42) NA L L L H L H
(43) U U U L L L H
(44) NA U L L H L H
(45) NA L L L H L H
(46) NA L L L H L H
(47) NA U L L H L H
(48) U U U L L L H
(49) U U U L L L H
Apixaban studies
(36) L U U L L L H
(53) L U U L H L H
(54) NA U U L H L H
(55) NA L L L H L H
H ¼ high; L ¼ low; QUADAS-2 ¼ Quality Assessment of Diagnostic Accuracy Studies 2; U ¼ unclear; other
abbreviations as in Table 2.
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1135steady-state concentrations of apixaban have been
published by Frost et al. (52) and are shown in
Table 1.
Study se lect ion . Our literature search for apixaban
yielded 70 articles; 3 additional references were
identiﬁed from bibliographies. Sixty-nine articles
were excluded: 68 did not report an original research
study and 1 was published as an abstract only. The
remaining 4 articles (37,54–56) met eligibility criteria
(Figure 1). Eligible studies collectively evaluated
apixaban across a range of concentrations from 0 to
2,500 ng/ml (Table 4).
Prothrombin t ime/ internat iona l normal i zed
rat io . We found 3 studies that reported the rela-
tionship between the PT and apixaban levels. One
study used both spiked normal plasma and ex vivo
plasma from apixaban-treated patients (37), another
used spiked plasma as well as ex vivo plasma from
healthy volunteers taking apixaban (55), and the
third study included only spiked normal plasma
samples (56) (Table 4). For the 2 studies that used
ex vivo plasma, the relationship was linear in one (37)
and curvilinear in the other (55). Correlation was
modest, with R2 values of 0.36 and 0.41, respectively.
Across in vitro and ex vivo samples and for a variety
of reagents, the PT was inadequately sensitive to
apixaban, not only below, but also above the ex-
pected trough concentration of 50 ng/ml.
Act ivated part ia l thromboplast in t ime . Only 1
study compared apixaban concentrations with APTT
(Table 3), which was measured using 10 different
APTT reagents in normal plasma samples spiked with
10 different concentrations of apixaban. The sensi-
tivity of the APTT was unacceptably low; all assays
yielded a ratio of 1.1 times control when the spiked
apixaban concentration was 100 ng/ml (i.e., twice the
expected trough concentration).
Ant i -Xa act iv i ty . Three studies compared anti-Xa
activity measurements with the plasma concentra-
tion of apixaban (Table 4). In 2 of the studies (37,54),
ex vivo patient samples were used, whereas the third
study (56) included only spiked samples of normal
plasma. In general, the relationship was linear at all
apixaban concentrations, with R2 values ranging from
0.89 to 0.97. Available evidence suggests that an
anti-Xa assay calibrated with LMWH standards will
also correlate linearly with apixaban concentrations
(37,54).
STUDY QUALITY. Assessment of study quality using
QUADAS-2 criteria (7) highlighted several recurrent
methodological concerns among eligible studies
(Table 5). Many studies used in vitro samples or
ex vivo samples from healthy controls rather thanex vivo patient samples. Concern about the applica-
bility of these studies to clinical practice within the
patient selection domain was judged to be high. Some
studies examined assays not widely available to cli-
nicians (e.g., ECA, ECT, dilute TT). Concern regarding
applicability of these studies to clinical practice
across the index test domain was judged to be high.
Because data correlating plasma NOAC levels and
clinical outcomes are scarce, concern about the
CENTRAL ILLUST
Within, and Above T
and Apixaban
Horizontal bars and
ability (i.e., sensitivit
above typical on-the
are approximations a
drug levels are show
ECA ¼ ecarin chrom
TT ¼ thrombin time
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1136applicability of the reference standard (plasma drug
concentration) to clinical practice was judged to be
high for all eligible studies.
DISCUSSION
This systematic review sought to examine evidence
for laboratory measurement of the anticoagulant
activity of dabigatran, rivaroxaban, and apixaban.
Although data on the relationship between plasma
NOAC levels and clinical outcomes are beginning to
emerge (57), there is, as yet, no evidence that
routine monitoring or dose titration will improve
outcomes. Nevertheless, measurement may be use-
ful in 3 circumstances: 1) to determine if very high
levels are present (in the case of suspected excess
effect [e.g., due to overdose or bioaccumulation]);
2) to determine if drug is present in typical on-
therapy ranges (e.g., in the case of suspected ther-
apeutic failure); and 3) to determine if any clinically
relevant drug effect is present (e.g., in the case of
bleeding or planned invasive procedures). An ideal
assay would thus show adequate linearity, sensi-
tivity, and reproducibility to enable quantiﬁcationRATION Sensitivity and Linearity of Coagulation Assays to Below,
ypical On-Therapy Concentrations of Dabigatran, Rivaroxaban,
vertical hatching correspond to the approximate range of detect-
y) and linearity, respectively, of each assay to below, within, and
rapy concentrations of dabigatran, rivaroxaban, and apixaban. Ranges
nd may vary on the basis of choice of reagent. Typical on-therapy
n in Table 1. APTT ¼ activated partial thromboplastin time;
ogenic assay; ECT ¼ ecarin clotting time; PT ¼ prothrombin time;
.across a broad range of drug levels. Apart from
LC-MS/MS, a test generally restricted to select
reference laboratories, no single coagulation assay
meets these idealized standards. Therefore, it is
important for clinicians to be aware of how coagu-
lation tests perform at NOAC concentrations below,
within, and above typical on-therapy ranges (Central
Illustration).
DABIGATRAN. The effect of dabigatran on various
coagulation assays is summarized in the Central
Illustration. The TT is exquisitely sensitive to dabi-
gatran. A normal TT excludes the presence of clini-
cally relevant drug levels; however, the assay is too
sensitive for quantiﬁcation within and above the on-
therapy range. The dilute TT, ECT, and ECA show a
high degree of linearity at drug levels >50 ng/ml and
are thus useful for quantiﬁcation across the entire
on-therapy range. They may be unreliable at con-
centrations below this threshold. The APTT is rela-
tively insensitive to dabigatran; a normal APTT may
not exclude clinically relevant below or within on-
therapy drug levels. The curvilinear response of
APTT at higher drug levels does not permit accurate
quantiﬁcation. The PT has even poorer sensitivity
and may be normal within much of the on-therapy
range.
RIVAROXABAN. Anti-Xa activity measured using
chromogenic substrates and rivaroxaban or heparin/
LMWH calibrators correlates linearly with rivarox-
aban over a wide range of concentrations (20 to 660
ng/ml) (Central Illustration). When rivaroxaban cali-
brators are used, anti-Xa assays can provide a
quantitative measure of rivaroxaban concentration.
A negative anti-Xa assay likely excludes clinically
relevant rivaroxaban levels. Although rivaroxaban
prolongs the PT, assay results vary markedly with
different thromboplastin reagents. A normal PT does
not rule out the presence of clinically signiﬁcant
below or within on-therapy rivaroxaban concentra-
tions; however, a prolonged PT qualitatively in-
dicates the drug’s presence. The APTT is not
suitable for measuring rivaroxaban due to the
nonlinear relationship with rivaroxaban concentra-
tion, poor sensitivity, and signiﬁcant variability be-
tween reagents.
APIXABAN. Although both the PT and APTT may be
prolonged in the presence of apixaban, neither is
sufﬁciently sensitive to exclude the presence of
clinically relevant on-therapy drug concentrations
(Central Illustration). Anti-Xa activity measurements
demonstrate a strong linear correlation with apixaban
concentration; the absence of detectable anti-Xa
TABLE 6 Suggestions for Laboratory Measurement of Non–Vitamin K Oral Anticoagulants
Drug
Clinical Objective
Determine If Clinically Relevant Below
On-Therapy Drug Levels Are Present
Estimate Drug Levels Within
On-Therapy Range
Determine If Above
On-Therapy Drug Levels Are Present
Suggested
Test Interpretation
Suggested
Test Interpretation
Suggested
Test Interpretation
Dabigatran TT Normal TT likely excludes clinically
relevant drug levels
Dilute TT,
ECA, ECT
— APTT, dilute TT,
ECA, ECT
Normal APTT likely excludes
excess drug levels; only
dilute TT, ECA, and ECT
are suitable for quantitation
Rivaroxaban Anti-Xa Normal anti-Xa activity likely excludes
clinically relevant drug levels
Anti-Xa — Anti-Xa, PT Normal PT likely excludes excess
drug levels; only anti-Xa is
suitable for quantitation
Apixaban Anti-Xa Normal anti-Xa activity likely excludes
clinically relevant drug levels
Anti-Xa — Anti-Xa —
Suggestions for laboratory measurement of the anticoagulant activity of dabigatran, rivaroxaban, and apixaban are based on the clinical objective. Typical on-therapy drug levels are shown in Table 1.
Abbreviations as in Table 2.
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1137activity (whether the standard curve is established
with apixaban or LMWH) likely excludes the presence
of physiologically important apixaban activity.
SUGGESTIONS AND COMPARISONS WITH GUIDANCE
DOCUMENTS. Recommendations for laboratory mea-
surement of the NOACs differ by drug and clinical
objective. The ﬁndings of our systematic review
support the suggestions summarized in Table 6.
These suggestions align with recommendations
provided in drug labels and published guidance
documents, with 2 notable exceptions. First, we
found strong evidence from studies of ex vivo pa-
tient samples that a normal APTT does not deﬁni-
tively exclude on-therapy dabigatran concentrations
(23,25). This observation is at variance with guide-
lines from the American Society of Hematology
(ASH) and the British Committee for Standards in
Haematology (BCSH), which state that a normal
APTT is likely to exclude therapeutic intensity
dabigatran (58) or contribution of dabigatran to
bleeding (59). Second, we found that a normal PT
does not exclude clinically relevant rivaroxaban
levels. The BCSH statement, in contrast, comments
that a normal PT ratio with most reagents excludes
therapeutic intensity rivaroxaban (58). The ASH and
BCSH statements were published in 2011 and 2012,
respectively. Discrepancies between our ﬁndings and
these statements may reﬂect availability of new in-
formation since their publication regarding a wider
variety of test reagents and their sensitivity to the
NOACs.
STUDY LIMITATIONS. Quality assessment high-
lighted several key limitations of eligible studies
(Table 5). First, on-therapy ranges (Table 1) werederived from pharmacokinetic analyses. We resisted
the term “therapeutic range” because data on how
these ranges correlate with clinical outcomes are
sparse, although they are beginning to emerge (57).
Second, many eligible studies used either ex vivo or
spiked plasma samples from healthy controls rather
than ex vivo samples from NOAC-treated patients.
Reassuringly, results obtained with patient samples
generally aligned with those from healthy controls.
Third, we identiﬁed only 4 eligible apixaban studies,
just 2 of which used ex vivo patient samples. Because
apixaban was the most recent NOAC to receive reg-
ulatory approval, we expect that additional studies
of its laboratory measurement will be forthcoming.
Such studies are also needed for NOACs not yet
approved in North America and Europe (e.g.,
edoxaban).
CONCLUSIONS
A relatively large number of published studies have
assessed the relationship between coagulation tests
and levels of dabigatran, rivaroxaban, and apixaban.
Each drug produces unique effects on coagulation
assays. Our systematic review provides guidance to
the clinician on how to use and interpret coagulation
test results in NOAC-treated patients. Further studies
are needed to deﬁne the relationship between drug
levels, coagulation test results, and clinical outcomes.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE 1: Pro-
thrombin time (PT) and activated partial thromboplastin
time (APTT) do not show sufﬁcient sensitivity or linearity
for quantiﬁcation of dabigatran, rivaroxaban, or apixaban.
A normal PT and/or APTT may not exclude clinically
relevant anticoagulant effects of these drugs.
COMPETENCY IN MEDICAL KNOWLEDGE 2: A
normal thrombin time likely excludes clinically relevant
plasma levels of the direct thrombin inhibitor dabigatran.
Dilute thrombin time and ecarin-based assays may be
used to measure dabigatran activity.
COMPETENCY IN MEDICAL KNOWLEDGE 3: An
anti-Xa assay using drug-speciﬁc calibrators may be
used to measure the activity of the factor Xa inhibitors
rivaroxaban and apixaban.
COMPETENCY IN PATIENT CARE: The NOACs
dabigatran, rivaroxaban, and apixaban do not require
laboratory monitoring of coagulation during routine
clinical use, but measurement of their anticoagulant
effect may be desirable in certain circumstances.
TRANSLATIONAL OUTLOOK: Development of
laboratory assays for measurement of the anticoagulant
activity of these NOACs is a high priority. Ideally, these
assays should be sufﬁciently sensitive to detect all
clinically relevant drug concentrations, show linearity
across a wide range of concentrations to permit
quantiﬁcation, and be reproducible and simple to perform
at the point of care.
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